Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia

Eireen Tang1 | Mariam Zaidi1 | Wen-Huey Lim1 | Vijayendran Govindasamy1 | Kong-Yong Then2 | Khong-Lek Then1 | Anjan Kumar Das3 | Soon-Keng Cheong4

1CryoCord Sdn Bhd, Bio-X Centre, Cyberjaya, Malaysia
2Brighton Healthcare (Bio-X Healthcare Sdn Bhd), Bio-X Centre, Cyberjaya, Malaysia
3Department of Surgery, IQ City Medical College, Durgapur, India
4Faculty of Medicine & Health Sciences, Universiti Tunku Abdul Rahman (UTAR), Kajang, Malaysia

Correspondence
Vijayendran Govindasamy, Research and Development Department, CryoCord Sdn Bhd (567828-A), Suite 1-1, 1st Floor, Bio-X Centre, Persiaran Cyberpoint Selatan, Cyber 8, 63000 Cyberjaya, Selangor, Malaysia.
Email: vijayendran@cryocord.com.my

Funding information
This review is part of a research project supported by CryoCord Internal Grant (Grant Number: POD0035/IR/B) awarded to the Principal Investigator, Dr. Vijayendran Govindasamy.

Abstract

Objective: Preterm infants are at a high risk of developing BPD. Although progression in neonatal care has improved, BPD still causes significant morbidity and mortality, which can be attributed to the limited therapeutic choices for BPD. This review discusses the potential of MSC in treating BPD as well as their hurdles and possible solutions.

Data Sources: The search for data was not limited to any sites but was mostly performed on all clinical trials available in ClinicalTrials.gov as well as on PubMed by applying the following keywords: lung injury, preterm, inflammation, neonatal, bronchopulmonary dysplasia and mesenchymal stem cells.

Study Selections: The articles chosen for this review were collectively determined to be relevant and appropriate in discussing MSC not only as a potential treatment strategy for curbing the incidence of BPD but also including insights on problems regarding MSC treatment for BPD.

Results: Clinical trials regarding the use of MSC for BPD had good results but also illustrated insights on problems to be addressed in the future regarding the treatment strategy. Despite that, the clinical trials had mostly favourable reviews.

Conclusion: With BPD existing as a constant threat and there being no permanent solutions, the idea of regenerative medicine such as MSC may prove to be a breakthrough strategy when it comes to treating BPD. The success in clinical trials led to the formulation of prospective MSC-derived products such as...
as PNEUMOSTEM®, and there is the possibility of a stem cell medication and permanent treatment for BPD in the near future.

**KEYWORDS**
chronic lung department, extremely low gestational age newborns (ELGANs), mesenchymal stem cells, PNEUMOSTEM, preterm infants, respiratory diseases

## 1 | INTRODUCTION

Despite a considerable number (241) of in-human clinical trials registered in ClinicalTrials.gov and the progression in neonatal medicine witnessed in the last five decades, the problem of lack of good therapeutic alternatives for bronchopulmonary dysplasia (BPD) continues to exist. Treatment strategies (Table 1) ranging from medications (antibiotics and diuretics) to steroid treatments all proved incapable of curing BPD and instead only aimed to aid the breathing of afflicted individuals.1–8 As the occurrence of BPD correlates with prematurity and extremely low gestational age newborns (ELGANs), with approximately every 50 000 ELGANs born, the numbers that develop BPD exceeds that of 18 000.9 The past few decades have witnessed a plateau of about 40% in the incidence of BPD within infants of less than or equal to 28 weeks gestational age (GA).10–12 However, based on the data acquired from cohort studies including Canadian, Korean, Swiss Neonatal Networks, Vermont-Oxford Network, and research in China, Taiwan, and India, the prevalence of BPD lies between 11% and 50%.9 This marks out BPD as a constant and persistent threat in every community, desperately calling for the need of a new, innovative and comprehensive treatment strategy.

A condition often unspoken about in the community, BPD remains listed as one of the frequent players in the chronic lung disease department in children under 5, third only to asthma and cystic fibrosis. It is one of the most prevalent and severe respiratory complications

| Interventions                                 | Clinical response                                                   | Side effects                                      | References |
|-----------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------|------------|
| Bronchodilators                               | Reduce pulmonary resistance                                         | Tachycardia, hypokalaemia, arrhythmias, and hyperglycaemia | 1–3        |
| Caffeine                                      | Anti-inflammatory and reduce dependency on mechanical ventilation    | Reduce weight gain                                | 1–4        |
| Diuretics                                     | Improve pulmonary oedema and decrease pulmonary vascular resistance | Ototoxicity, electrolyte disturbances, and azotaemia | 1–4        |
| Fluid restriction                             | Improve pulmonary oedema and reduction in BPD incidence/severity    | May interfere with the recommended nutrient intake | 5          |
| Steroids (systemic, inhaled)                  | Anti-inflammatory and improve oxygenation                            | Hyperglycaemia, gastrointestinal perforation, and hypertension | 1,3,6,7    |
| Inhaled nitric oxide (NO)                     | Ongoing evaluation                                                  | No side effects reported, ongoing evaluation      | 1          |
| Inositol                                      | Improve pulmonary function and reduce BPD incidence/mortality        | No side effects reported                          | 1–3        |
| Macrolide antibiotics                         | Anti-inflammatory and reduce BPD incidence and mortality rate        | No side effects reported                          | 4          |
| Nutrition supplementation                     | Prevent growth failure of infants                                    | No side effects reported                          | 5,6        |
| Supplemental oxygen/ventilator support        | Improve oxygenation                                                 | Require hospitalization/home oxygen therapy        | 1          |
| Surfactant                                    | Decrease mortality and severity of respiratory distress syndrome     | No side effects reported                          | 2,4,6      |
| Vitamin A                                     | Improve lung development and growth                                  | High cost and low availability                    | 1–4,6      |
resulting from extreme prematurity. Described as a chronic lung disease which leads to the requirement of mechanical ventilation and oxygen therapy during infancy and long-term respiratory effects in adults, BPD causes a depletion in alveolarization, vascular growth and lung function, resulting in perinatal inflammation and oxidative stress, all of which consequently disrupt lung development. Its occurrence is most observed in preterm infants who are born at 24–26 weeks of gestation with a birth weight of less than 1000 g, forcing the infants to require and rely on extensive oxygen therapy and ventilation support for survival. Children with BPD are also more prone to developing cognitive and motor impairment, speech, language, visual and auditory disorders, and behavioural problems.

2 | PATHOPHYSIOLOGY OF BPD

BPD possesses a multifactorial aetiology comprising preand post-natal agents responsible for detrimental alveolar growth with preterm birth being the governing factor. This includes perinatal inflammation and infection, oxygen toxicity combined with declining host antioxidant defences, mechanical ventilation, patent ductus arteriosus and postnatal infection with the additive influence of genetic factors as major causative agents of BPD. Studies have also characterized preeclampsia as another causative agent. Disrupted signalling of vascular endothelial growth factor (VEGF) and impaired angiogenesis in preeclampsia are additional factors associated with BPD development.

2.1 | Lung development

Lung development begins between 3 and 6 weeks of gestation where efficient respiration depends on the structure of peripheral lung saccules and alveoli. At 28–40 weeks of gestation, the peripheral lung saccules undergo septation wherein the airspaces are divided thus elevating the number of alveoli, consequently magnifying the surface area for gas exchange. The peripheral lung epithelial cells develop into alveolar type 1 and type 2 cells out of which, alveolar type 2 processes pulmonary surfactant. Therefore, premature infants at 22–23 weeks GA start ventilation at the canalicular–saccular stage of lung development which is prior to the completion of morphogenesis and alveolar differentiation. Premature birth within the early stages of saccular phase is accompanied by impaired lung development and septation. Subsequently, infection, ventilation and supplemental oxygen provokes the pro-inflammatory pulmonary response which in turn impacts healthy lung development leading to a reduction in the number of alveoli and diminished alveolar anatomy leading to a decrease in gas exchange surface area. Furthermore, lung growth during the alveolar phase fails to generate an updated development leading to detrimental lung functionality persevering into adulthood. A deviated pulmonary vascular growth due to impaired air-conducting segments of the lung were seen within patients with severe BPD resulting in a situation of dual limitation of gas transport caused by restricted lung surface area and decreased capillary network.

2.2 | Pulmonary surfactant

An effective structure, function and metabolism of surfactant within the alveolus depends on a combination of phospholipids such as phosphatidylcholine and proteins including SP-A, SP-B, SP-C and SP-D. The formation of these surfactant lipids and proteins is dependent on differentiating alveolus type 2 cells occurring during late gestation. However, when the body is low on pulmonary surfactant due to unfinished differentiation, an illness known as respiratory distress syndrome (RDS) develops amongst infants. Although administering exogenous pulmonary surfactant within infants lowers oxygen requirement and mechanical ventilation within preterm infants, it increases their risk of acquiring BPD.

2.3 | Patent ductus arteriosus

Patent ductus arteriosus (PDA) is linked with deleterious respiratory outcomes and a study by Brown hinted at the correlation between BPD and PDA, specifically amidst infants with extremely low birth weight. Another study established the increasing risk of BPD in premature infants weighing between 500 and 1000 g upon the synchronicity of PDA and infection. Rojas et al. determined that significant causative agents of BPD included PDA, sepsis and low birth weight where the inclusion criteria involved (1) premature infants weighing between 500 and 1000 g upon the synchronicity of PDA and infection. The co-occurrence of PDA and sepsis, have increasing odds for BPD compared with infants devoid of these symptoms.
2.4 | Mechanical ventilation

The implementation of positive pressure ventilation for preterm infants could lead to BPD due to mechanical lung overdistension and alveolar stretch. This happens as excess volume and pressure can cause lung damage by overinflating the alveoli, causing cellular injury, inflammation and reactive oxygen species (ROS) generation, which contributes to the amplification of injury caused by prenatal inflammation.28

2.5 | Oxygen toxicity

Oxygen toxicity is another risk factor of BPD as it has been observed in animal models that supraphysiologic oxygen solely compromises alveolar development and pulmonary vascular remodelling. These models have showcased long-term modifications of the lung upon exposure to high concentrations of oxygen.29,30 Clinical details suggest that even a slight exposure of supraphysiologic oxygen whilst resuscitating enhances BPD risk and development.31 Moreover, preterm infants are prone to experiencing oxidative stress due to underdeveloped antioxidant defences, vulnerability to infection and subjection to free iron.32

2.6 | Genetic predisposition

Having recently emerged as a possible agent in BPD development, genetic predisposition is a potential causative factor of BPD as reported by Bhandari et al.33 wherein 450 pairs of twins were assessed where hereditary and shared environmental agents account for 65% of variances in BPD sensitivity.28 Numerous other studies also address the linkage between genetic polymorphisms and BPD development.34–37

2.7 | BPD phenotype

Preterm infants who at birth are small for gestational age or possess intrauterine growth restriction (IUGR) have a higher risk of acquiring pulmonary damage.5,38 For instance, researchers have determined a twofold elevated risk of BPD (28% vs. 14%) and neonatal mortality (23% vs. 11%) in preterm infants with small gestational

![LUNG PATHOPHYSIOLOGY](image)
Preterm infants born less than 27 weeks of gestation showed growth failure which contributes to the risk of BPD development. As a result of BPD, it can be observed in changes of lung pathophysiologic of the affected patients. A summary of the affected lung pathophysiology can be seen in Figure 1.

3 | MESENCHYMAL STEM CELLS AS A TREATMENT FOR BPD

Through an increase in stem cell research, scientists have established the therapeutic properties of stem cells, which are undifferentiated cells that possess the ability to differentiate into specialized cells. This contributes to their characteristics of self-renewal, organogenesis, maintenance, repair and tissue regeneration. For instance, MSCs, a class of adult stem cells obtained from mesoderm, exhibit the benefits of easy isolation and expansion in addition to displaying multipotency and pleiotropy in several injury models due to which they are highly effective in stem cell biology. Their incorporation in the treatment of neonatal lung injuries has showcased the capability of MSCs to protect lungs and implement paracrine-mediated activity for therapeutic benefits such as decreased immunogenicity and non-tumourigenicity. Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are easily acquired, highly proliferative and exhibit an immensely high paracrine action when compared with other sources. Their therapeutic activity is proven through their ability to reduce lung inflammation, fibrosis, angiogenesis and apoptosis in several animal pulmonary disease models displaying pulmonary fibrosis and acute lung injuries, which include BPD.

The idea of incorporating the regenerative properties of MSCs as a possible treatment strategy for BPD was put into motion with the first in-human clinical trial submitted by Medipost Co. Ltd. in December 2010 in South Korea (NCT01297205). Their success in proving the safety and feasibility of stem cell incorporation for BPD led to the introduction of PNEUMOSTEM®, a product of allogeneic sources of stem cells derived from human umbilical cord blood (hUCB-MSCs). As of late, the clinical trials concerning PNEUMOSTEM® have reached phase II clinical trials with the trials currently ongoing in South Korea along with its passing phase II in the United States. Due to its excellent potential and milestones unachievable by other stem cell products, it has been designated as an Orphan Drug by the US FDA and EMA for the trial in South Korea in addition to being granted a Fast-Track Designation from the US FDA. That same trial then became the standard for all the clinical trials that followed in investigating the use of stem cells for BPD.

As of late, there exists multiple in-human clinical trials concerning the use of stem cells for BPD with most of them, if not all, managing to prove their safety and feasibility with more products under development. Notable products under development include UNEX-42, first introduced by United Therapeutics. The product is a relatively new approach to stem cell therapy for BPD as it is prepared from the extraction of extracellular vesicles from allogeneic sources of stem cells obtained from the bone marrow. Currently, UNEX-42 is still under an ongoing trial situated in phase I and is estimated to be completed by the end of 2021 (NCT03857841). Another product to look forward to will be Meridigen’s product, labelled as UMC119-01. The source of UMC119-01 are stem cells derived from the umbilical cords of neonates. This study is currently still in the recruiting phase and is expected to be completed nearing the end of 2022 (NCT03631420). The list of clinical trials regardless of its completion status is as listed in Table 2.

4 | MECHANISM OF ACTION AGAINST BPD

What makes MSCs a highly sought-after treatment plan for BPD lies in their hypothesized means of action that explains their therapeutic capabilities. Contrary to the initial hypothesized belief that the innate regenerative and differential capabilities of MSCs is responsible in ameliorating BPD, the idea that there is another mechanism besides the engraftment of MSCs was ascertained. Chang et al. could not form a direct connection between the mechanism of repair and regeneration of MSCs against lung injury. The idea that there is no need for the MSCs itself was reported where MSC-conditioned media (MSC-CM) presented a profound effect in preventing alveolar injury, preserving normal lung function and stimulating bronchoalveolar stem cells (BASCs) when compared with the introduction of bone marrow stem cells (BMSCs) themselves.

In vivo studies both showed very low levels when introduced in BPD models that suggests that the engraftment of MSCs is not suitable as the primary mechanism in terms of lung protection. Hence, for BPD, the main mechanism is hypothesized to be through paracrine signalling involving the release of specific soluble factors which triggers a cascade of events that can result in immunomodulation, antioxidation, anti-inflammation and the release of signalling peptides. A summary of the mechanism of action of MSCs towards BPD is as shown in Figure 2.
| Study                                | NCT number       | Cell type       | Route                | Number of patients (n) | Dosage (million cells/kg) |
|--------------------------------------|------------------|-----------------|----------------------|------------------------|---------------------------|
| **MSC drug on-going clinical trials**|                  |                 |                      |                        |                           |
| Medipost Co Ltd<sup>51,52</sup>      | NCT02023788      | PNEUMOSTEM      | Intratracheal        | 8                      | 10–20                     |
|                                      | NCT04003857      |                 | Intratracheal        | 60                     | 10                        |
| United Therapeutics<sup>49</sup>     | NCT03857841      | UNEX-42         | Not specified        | 18                     | 20–200 pmol phospholipid/kg|
| Meridigen Biotech Co., Ltd.<sup>50</sup> | NCT03631420  | UMC119-01       | Not specified        | 9                      | 3–30                      |
| **Phase II**                         |                  |                 |                      |                        |                           |
| Medipost America Inc.<sup>53</sup>  | NCT02381366      | hUCB-MSCs       | Intratracheal        | 12                     | 10–20                     |
| Children’s Hospital of Fudan University<sup>52</sup> | NCT03645525 | hUC-MSCs        | Intratracheal        | 180                    | 20                        |
| Children’s Hospital of Chongqing Medical University<sup>54</sup> | NCT03774537 | hUC-MSCs        | Intravenous           | 20                     | 1–5                       |
| Children’s Hospital of Chongqing Medical University<sup>55</sup> | NCT03601416 | hUC-MSCs        | Intravenous           | 72                     | 2.5–5                     |
| Medipost Co. Ltd<sup>56</sup>       | NCT03392467      | hUC-MSCs        | Intraperitoneal       | 60                     | Not specified              |
| **Phase I**                          |                  |                 |                      |                        |                           |
| Medipost Co. Ltd<sup>57</sup>       | NCT01297205      | hUCB-MSCs       | Intratracheal        | 9                      | 10–20                     |
| Samsung Medical Center<sup>57</sup> | NCT01632475      | hUCB-MSCs       | Intratracheal        | 9                      | 10–20                     |
| Children’s Hospital of Chongqing Medical University<sup>58</sup> | NCT03558334 | hUC-MSCs        | Intravenous           | 12                     | 1–5                       |
| Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Caja<sup>59</sup> | NCT02443961 | hUC-MSCs        | Not specified        | 10                     | 5                         |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University<sup>60</sup> | NCT03378063 | hUCB-MSCs       | Not specified        | 100                    | Not Specified              |
| Children’s Hospital of Chongqing Medical University<sup>61</sup> | NCT03873506 | hUC-MSCs        | Intravenous           | 30                     | 1–5                       |
| Guangdong Women and Children Hospital<sup>62</sup> | NCT03683953 | MSCs            | Intratracheal        | 200                    | 25                        |
| China Medical University Hospital<sup>63</sup> | NCT01207869 | UC-MSCs         | Intratracheal        | 10                     | 3                         |
| Ottawa Hospital Research Institute<sup>64</sup> | NCT04255147 | Allogeneic UC-MSCs | Intravenous         | 9                      | 1–10                      |
| Vinmec Research Institute of Stem Cell and Gene Technology<sup>65</sup> | NCT04062136 | hUC-MSCs        | Endotracheal and     | 10                     | 1                         |
|                                      |                  |                 | Intravenous          |                        |                           |

(Continues)
4.1 | Paracrine signalling

4.1.1 | Extracellular vesicles (exosomes)

Nanometer-size extracellular vesicles/microvesicles known as exosomes are important mediators of intercellular signalling by the constituents, they carry which can vary between mRNA, miRNA and effector proteins, involved in altering gene expressions.\(^75\)-\(^77\) MSC-derived exosomes follow the exocytosis pathway where they are secreted by multivesicular bodies (MVBs) when fused with the plasma membrane.\(^78\) The release of the exosomes allows for a change in biological processes mediated by their wide range of properties ranging from their regenerative ability to their immunomodulatory and disruptive properties with regards to the pathogenesis of various diseases including inflammatory diseases.\(^76\) Following the fusion, the exosomes are released to interact with target cells in the micro-environment or transported to targeted regions through biological fluids. In vivo studies against BPD in animal models showed the effectiveness of MSC-derived exosomes in mediating pulmonary hypertension arising from BPD and the disease as an overall and an increase in lung compliance as a whole when compared with MSCs without the presence of exosomes.\(^13,79\) Dong et al.\(^80\) studied the relationship between miRNAs and the incidence of BPD where a strong correlation was found, suggesting that the exosome release mediated by MSCs could play a vital role in reversing BPD by altering/silencing gene expressions accordingly. Furthermore, Cho et al.\(^81\) found that MSC exosomes can decrease the eosinophil level, number of IgE and CD86\(^+\) cells in atopic dermatitis model that mimics the BPD environment.

Research centring around MSC-derived exosomes is important in understanding its mechanism as a therapeutic treatment method for BPD, considering the positive results seen in BPD models. The role of MSC-derived exosomes and its exact mechanism is yet to be elucidated; however, its role in facilitating mitochondrial transfer together with its potential immunomodulatory function is heavily endorsed. Willis et al.\(^82\) suggested a possibility where MSC-derived exosomes can exert their anti-inflammatory properties in BPD models by reprogramming the recipient’s immune system. More specifically, altering the phenotype of existing pulmonary macrophages through a shift in the M1/M2 ratio present in macrophages which are the pro and anti-inflammatory markers, respectively. The mitochondria constituent of exosomes is expected to be transferred to resident pulmonary cells including macrophages. Additionally, its immunomodulatory property is made possible due to the presence of an anti-inflammatory protein, TNF-
stimulated gene 6 protein (TSG-6) in MSCs. Both mechanisms interconnected with the release of exosome bodies will be elaborated upon in the following sections.

4.2 | Immunomodulation

MSCs have been found to be capable of interacting with both the innate and adaptive immune system, successfully lowering the immunogenicity and managing to go around it in a way as to not provoke an immune response. TSG-6, an inflammatory exosome protein, is composed of link modules, enabling its binding to notable glycosaminoglycan, including that of hyaluronan and chondroitin sulphate. Hyaluronan is involved in processes surrounding inflammation where it acts to stabilize the extracellular matrix, maintaining structural and functional integrity. The bound TSG-6-hyaluronan complex can interact with CD44 receptor, a cell surface glycoprotein present on macrophages. Once the interaction is successful, one of the three main inflammatory pathways, the action of the NF-κB pathway is then reduced where inflammation is subdued. Moreover, Mittal et al. published findings wherein TSG-6 promotes the conversion of macrophages from pro-inflammatory to an anti-inflammatory composition by suppressing pro-inflammatory transcription factors. Furthermore, neutrophil migration to the inflammation site is also inhibited. Bryan et al. and Chaubey et al. reported a decrease in lung apoptosis and a major improvement in alveolar disruption in BPD models treated with MSCs where high levels of TSG-6 were present in the lung tissues, supporting the theory concerning the role of TSG-6.

MSCs are also able to inhibit the action of immune cells, B cells, dendritic cells and natural killer cells by suppressing their proliferative activity or by stimulating the expression of certain immune cells. BPD affects the resident pulmonary immune cells possibly because of an imbalance in the levels of pro and anti-inflammatory cytokines. These events are orchestrated by the release of immunomodulatory factors who are important pulmonary biomarkers of BPD transforming growth factor-β1 (TGF-β1), IL-6, IL-10, IL-16 and so forth. What ensues is a rise in macrophages and neutrophil levels seen in infants with BPD complications to repair and restore the damage inflicted on the lungs. The addition of MSCs are expected to balance up the levels of both pro and anti-inflammatory cytokines by decreasing and increasing the levels accordingly. Immunomodulatory functions of MSCs against BPD are proposed as the main mechanism behind MSCs where reduction in macrophage and neutrophil levels were observed upon MSC administration in vitro with evidence wherein MSC-CM prevented the proliferation of IL-1α and TNF-α, both pro-inflammatory cytokines resulting from activated macrophages. Aslam et al. supported the theory by enlisting murine models with attenuated lung injury. As a result, tissue repair was observed, and an improvement was seen.
in lung morphology. Similarly, MSC transplants in murine models with acute lung injury and bleomycin-induced lung injury and fibrosis showed a decrease in macrophage protein levels and an increase in releasing cytokines (IL-1ra) that can compete with pro-inflammatory cytokines (IL-1b). The immunomodulatory function of MSCs exosomes was also found to greatly affect pulmonary macrophages by mediating inflammation accompanying induced hyperoxia in animal models.

4.3 Mitochondrial transfer

There has been evidence suggesting the efficacy of cell-to-cell contact involving mitochondrial transfer from MSCs to the damaged cells to fill up for their inadequate respiratory function. The likelihood of mitochondrial transfer by TNT in bronchial epithelial cells was suggested through in vitro experiments. Protective outcomes with regards to mitochondrial transfer were seen in treating organ injury (lung, kidney, spinal cord etc.). MSC-mediated mitochondrial transfer functions to effectively mitigate any damage inflicted on the mitochondria and the bronchopulmonary system altogether, because of a plethora of reactive oxygen species (ROS) production bringing about oxidative stress onto the cells. Mitochondrial homeostasis is never achieved, leading to a damaged mitochondrion, like in the case of BPD. Various pathways have been identified which could possibly account for the transfer of mitochondria via actin-based structures such as tunnelling nanotubes (TNT), gap junctions, micro-vesicles and cellular fusion. The navigation of mitochondria to the site of cell injury is mainly mediated by Mitochondrial Rho GTPase 1 (Miro-1), an adaptor protein known to be involved in mitochondrial intercellular transport.

Miro-1 is part of a protein complex together with Myo 10, Myo 19, TRAK 1, TRAK 2 and KLF 5, which acts in regulating the transport mechanism of the mitochondria and subsequently allowing its movement through the cytoplasmic nanotubes. The importance of Miro-1 is confirmed in multiple studies where its expression enhances MSCs mitochondrial transfer efficiency and vice versa. The hypothesized mechanism in which MSCs can detect the respiratory damage brought upon by a damaged mitochondria lies in environmental cues released by the injured cells. These are in the form of the damaged mitochondria itself and its associated products (mtDNA, N-formyl peptides and lipids) where they play a vital role in inflammatory responses and are recognized by surrounding cells as damage-associated molecular patterns (DAMPs).

Mitochondrial transfer has shown its bioenergetic potential in lung conditions impacted by oxidative stress which is significant in the pathogenesis of BPD. The delivered mitochondria are able to conform to oxidative stress. This results in an increase in DNA/RNA production, positively affecting the number of respiratory enzymes along with oxygen consumption levels and preserving ATP/respiratory levels. Following alveolar/airway barrier disruption, a partial restoration in dysfunctional mitochondria accompanied by usual/normal oxidative phosphorylation levels, activated antioxidant pathways, and an improvement in lung health was observed when MSC mitochondria were present as compared with the introduction of MSCs in the absence of mitochondria. This demonstrated its significance by introducing BM-MSCs in vivo in mice models with induced acute lung injury. As a result, mitochondrial transfer took place through nanotubes and micro-vesicles where the restoration of mitochondrial bioenergetics in the lungs was observed. Another condition like the pathogenesis of BPD, chronic obstructive pulmonary disorder (COPD), was also experimented on where mitochondrial transfer took place, passing through TNT, reaching the lung epithelium tissues where alveolar damage was successfully restored. It was also suggested that mitochondrial transfer might possess anti-inflammatory potential, a key side effect of individuals suffering from BPD.

5 BARRIERS IN MSC THERAPY

Although trials incorporating MSC for BPD are limited, provided only a handful of clinical trials are completed with the rest currently ongoing, the statistics remain favourable towards the introduction of MSC as a permanent treatment strategy both in terms of safety as well as efficacy. However, with great success comes ever growing concerns that have to be addressed before stem cell products like PNEUMOSTEM®, UNEX-42 and UMC119-01 are ready to be marketed. A summary of the barriers and obstacles faced in developing MSC therapy can be found in Figure 3.
5.1 | Allogeneic vs autologous sources

Yang et al.\textsuperscript{111} assessed the safety of incorporating autologous hUCB in preterm infants (less than 37 weeks gestational age) for treatment of diseases including that of BPD. The treatment was considered a success where favourable results were obtained as no complications arose, nor were there any reported adverse events. This study proves the usage of autologous sources of MSCs for BPD; however it does not diminish the fact that there are a good deal of factors and questions to be taken into consideration. Will the amount of stem cells harvested be sufficient? Are the stem cells harvested healthy? Do they still maintain their regenerative and protective capabilities? Every individual is indeed different—their state of well-being, the amount of stem cells they have, their stem cell capability—which increases complexities should only autologous therapies be carried out. This explains why most clinical trials on stem cell therapy pertaining to BPD involved the use of allogeneic sources of MSCs rather than autologous sources. Allogeneic sources are not only more feasible and suitable for mass production to cater for a larger scale of research but they are also efficient in handling the concerns that autologous therapy poses. To ensure the stem cells harvested for allogeneic therapies do not carry the above concerns on its state and capacity, they can be harvested from healthy donors.\textsuperscript{112} It provides quality assurance and control on the stem cells being used together with the fact that it is less time consuming and cheaper considering the stem cells harvested can be used for administration within multiple BPD patients. The only downside to allogeneic therapy would be that they possess a considerably higher risk of graft-versus-host disease (GVHD) wherein the immune system is unable to recognize the cells and targets them as foreign, leading to the inevitable rejection of the allogeneic cells which is not a problem in autologous therapies.\textsuperscript{113} Implementation of cell-free supernatants is an approach that may overcome issues related to allogeneic therapy as results concluded from animal trials indicate the efficiency of MSC-based treatments is moderated, in BPD, mainly by paracrine activity.\textsuperscript{114}

5.2 | Heterogeneity

Heterogeneity of stem cells is attributed to the many different areas they can be harvested from. To name a few
are bone marrow, adipose tissue, dental pulp, cord blood, Wharton jelly and the placenta. The stem cells harvested differ in their characteristics. For instance, umbilical cord derived stem cells (hUCB-MSCs, hUC-MSCs and hAEC-MSCs) are preferable as compared with bone marrow derived stem cells as they are found to be easier to harvest coupled with advanced characteristics such as having a higher proliferative capacity, lower antigenic properties and a stronger paracrine effect. Contributions to the heterogeneity of MSCs lies in the sex of the donor. Sammour et al. reported that MSCs harvested from female donors displayed stronger paracrine effects with greater angiogenic and anti-inflammatory properties which resulted in an overall reduction in neonatal hyperoxia-induced lung diseases which are inclusive of BPD. The mechanism of action of MSCs against BPD relies heavily on its paracrine signalling. With that being so, there is no need for the MSC itself and an MSC conditioned media would suffice. This in itself causes variability when selecting the cell population with the most abundant humoral factors to be used and the same problem follows for exosomes. Looking at the pathophysiology of BPD, it is evident that it is a multifactorial disease, which requires a more precise selection on the MSC to be used based on its heterogeneity. Therefore, the emphasis on the need of a standardized isolation protocol that have been proven to be the most advantageous, fully utilizing the protective and regenerative effects of MSCs for BPD is called for.

5.3 Acquisition and manufacturing

The acquisition of raw materials for stem cell therapies is a complex process requiring aseptic processing protocols. Moreover, their mechanism within the body differs from medicinal drugs which makes the pharmacokinetics and pharmacodynamics challenging. To market stem cells as an ‘off-the-shelf’ medication for BPD, easily accessible in large bulks, large-scale manufacturing is a definite process. This whole process of scaling up involves a long and straining cycle from the collection, storage, process and cryopreservation of stem cells to the subjection of stem cells for further improvisation, formulating it to be suitable in accordance with the targeted therapies. Through analysis of suppliers and their rate of purity and sterilization techniques, high quality raw materials required for an uninterrupted and licensed medicinal product for advanced clinical trials can be secured following the success of early clinical phases. Moreover, to prevent contamination, raw materials can be aliquoted into desired vials and packaged immediately at the supplier firm. With the balance of standardization and customization in addition to introducing unique raw material formats, that is, instigation of kits, combining cytokines with media, and reconstitution cytokines, barriers adhering to timeliness and raw material stability can be overcome. Moreover, with standardization of products, the cost, manufacturing time and number of suppliers will be lowered in comparison with customized therapies. This technique also supports a larger number of BPD patients, accessibility, feasibility due to the reduced cost of manufacturing and ‘off-the-shelf’ medication. Personalized equipment designed in collaboration with the suppliers can also ease the process of manufacturing.

The original state of stem cells following subculturing gets compromised and the number of times where the cells are subjected to the cell culture cycle impacts the capacity of the stem cells as it is known that they are more susceptible to an impairment in immunomodulatory property as well as experiencing senescence. The prospect of genomic instability is also present from continuous expansion of the MSCs. Hence, the usage of MSCs is restricted to cells that are in the earlier subculturing stages to observe the full benefits of MSCs during BPD treatment. However, that statement is not fully validated as although there have been indications in which cryopreservation encourages functional impairment of the cells, the data gathered is also limited which prompts for more extensive research regarding this area. Researchers have observed and elucidated the genetic stability of hUC-MSCs expanded in vitro in cultures up to passage P13. However, the possibility of carcinogenic transformation of transplanted pluripotent cells is another risk factor that does not have a definitive solution. As karyotype analyses do not account for copy number variants (CNV) or mutations, the incorporation of array-comparative genomic hybridization (aCGH) at later passages prior to stem cell transplantation, quality control and long term follow ups for adverse events in neonates with BPD can be induced to ensure genetic stability.

5.4 Optimal dosage, administration period and route of administration

Undefined factors such as the optimal dosage, administration period and route are important factors that impact the effect of MSCs. Chang et al. demonstrated the efficacy of hUCB-MSCs on rodents with hyperoxia lung injuries and suggested the time-dependent nature of administration, where administration at an earlier stage could better the efficacy of the MSCs against BPD as compared with administration at a later stage. When
reviewing clinical trials that have been completed or are underway, the range of dosage given was significant (1–20 million cells/kg) and all doses were well tolerated in all patients which could suggest that the amount of MSCs given does not need to be restricted to a certain amount and as long as the amount administered is within the range provided by previous clinical trials, it is considered safe and effective. As for the number of doses to be administered, there is no conclusive data proving one option is more superior than the other, although multiple doses of MSC have shown greater efficacy in managing intraventricular haemorrhage, a condition highly associated with BPD.\textsuperscript{125} Besides that, all other factors listed remain unclear, including a standardized clinical protocol. To safely determine the effective dosage, including the number of doses needed and the best timeframe, more dose-escalation studies will prove beneficial in future clinical trials.

One of the most debated issues concerning MSC therapy for BPD is the route of administration, mainly the intratracheal and the intravenous pathway. Both have shown their efficacy with varying effects, with more research focused on the former pathway. Efficacy when administered intratracheally appeared to be better than when it was administered intravenously, but its usage was only restricted to preterm who are severely affected with BPD.\textsuperscript{114} The explanation lies in the fact that preterm infants, in general, are put on ventilator support for only a short period which emphasizes the need to transition mainly into the intravenous pathway. The selection of preterm infants to receive the stem cells is also an important factor. The absence of a reliable biomarker poses a problem in understanding and observing the therapeutic efficacies of the treatment using MSCs. With the presence of a biomarker, the selection of preterm infants is more reliable with the selection of only preterm infants with high risk of BPD incidence. Thus, effects resulting from the MSC treatment on preterm infants can also be easily predicted with minimal issues. The findings of a biomarker can further aid in the use of allogeneic sources of MSCs by heavily monitoring the BPD biomarker.\textsuperscript{114}

## 6 | CONCLUSION AND FUTURE PROSPECTS

With the advancement of technology and research in regenerative medicine, the development of MSC therapy may be a breakthrough in treatment of BPD within preterm infants. The emergence of numerous clinical trials in the recent years on MSC products such as PNEUMOSTEM®, UNEX-42 and UMC119-01 with successful results has proved the safety and practicality of integrating stem cell therapy as one of the treatments for BPD. However, with the ongoing clinical trials, there remain barriers and hurdles faced in developing an off the shelf MSC medication for BPD in which the processes involved in the formulation of the MSC product have been covered up till the manufacturing area with the same concerns in mind, how do we present the product in such a way that it can be marketed as an ‘off-the-shelf’ type of medication or otherwise as prescription medication? One particular area to keep sight off would be the form of the product it is marketed in, in the future. With the current trials focused on administrations that require expertise and a certain level of knowledge, there are health and ethical concerns that should the product be marketed as a ‘self-injection’ type of product, there is the assumption that the public is equipped with enough knowledge on how to self-administer or administer it on the affected infants. The need for regulations on the usage and/or prescription of said MSC drug must be looked into, to avoid abuse or misuse of the product. Another way is to investigate other possible routes of administration that can dispel those concerns. One of them would be to investigate the oral route of administration in future clinical trials. Bearing the heterogeneity of the stem cells in mind, in addition to the processes leading to the marketing of the product, more research and investigation is required before there can be the possibility of an ‘off-the-shelf’ and a ‘one-size-fits-all’ stem cell medication for BPD.

## ACKNOWLEDGMENTS

The authors thank CryoCord Sdn Bhd’s management for funding the study.

## CONFLICTS OF INTEREST

Kong-Yong Then, Khong-Lek Then and Soon-Keng Cheong are directors of CryoCord Sdn Bhd and declare direct share interest in the company whereas all other authors declare no conflict of interest.

## ETHICS STATEMENT

Ethics approval was not required for this study.

## AUTHOR CONTRIBUTIONS

V.G. contributed to the conceptualization and writing (original draft, review and editing) of the manuscript. E.T., M.Z. and W.H.L., contributed to the writing (original draft and review) of the manuscript. K.Y.T., K.L.T., M.G. A.K.D. and S.K.C. contributed to the writing (review and editing).
REFERENCES
1. Baveja R, Christou H. Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol. 2006;30(4):209-218. doi:10.1053/j.semperi.2006.05.008
2. Michael Z, Spyropoulos F, Ghanta S, Christou H. Bronchopulmonary dysplasia: an update of current pharmacologic therapies and new approaches. Clinical Medicine Insights: Pediatrics. 2018;12:1-12. doi:10.1177/1179556518817322
3. Tropea K, Christou H. Current pharmacologic approaches for prevention and treatment of bronchopulmonary dysplasia. Int J Pediatr. 2012;1-9. doi:10.1155/2012/598606
4. Gisondo CM, Donn SM. Bronchopulmonary dysplasia: an overview. Research and Reports in Neonatology. 2020;10:67-69. doi:10.2147/RNR.S271255
5. Poindester BB, Martin CR. Impact of nutrition on bronchopulmonary dysplasia. Clin Perinatol. 2015;42(4):797-806. doi:10.1016/j.clp.2015.08.007
6. Aschner JL, Bancalari EH, McEvoy CT. Can we prevent bronchopulmonary dysplasia? J Pediatr. 2017;189:26-30. doi:10.1016/j.jpeds.2017.08.005
7. Pasha AB, Chen XQ, Zhou GP. Bronchopulmonary dysplasia: pathogenesis and treatment. Exp Ther Med. 2018;16(6):4315-4321. doi:10.3892/etm.2018.6780
8. Kennedy KA, Cotten CM, Watterberg KL, Carlo WA. Prevention and management of bronchopulmonary dysplasia: lessons learned from the neonatal research network. Semin Perinatol. 2016;40(6):348-355. doi:10.1053/j.semperi.2016.05.010
9. Thébaud B, Goss KN, Laughon M, et al. Bronchopulmonary dysplasia. Bronchopulmonary Dysplasia Nature Reviews Disease Primers. 2019;5(1):78. doi:10.1038/s41572-019-0127-7
10. Day CL, Ryan RM. Bronchopulmonary dysplasia: new becomes old again! Pediatr Res. 2017;81(2):210-213. doi:10.1038/pr.2016.201
11. Lapcharoensap W, Gage SC, Kan P, et al. Hospital variation and risk factors for bronchopulmonary dysplasia in a population-based cohort. JAMA Pediatr. 2015;169(2):e143676. doi:10.1001/jamapediatrics.2014.3676
12. Zysman-Colman Z, Tremblay GM, Bandeali S, Landry JS. Bronchopulmonary dysplasia—trends over three decades. Pediatr Child Health. 2013;18(2):86-90. doi:10.1093/pch/18.2
13. Porzionato A, Zaramella P, Dedja A, et al. Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2019;316(1):L6-L19. doi:10.1152/ajplung.00109.2018
14. Nguyen LT, Trieu TTH, Bui HTH, et al. Allogeneic administration of human umbilical cord-derived mesenchymal stem/stromal cells for bronchopulmonary dysplasia: preliminary outcomes in four Vietnamese infants. J Transl Med. 2020;18(1):398-410. doi:10.1186/s12967-020-02568-6
15. Gien J, Kinsella JP. Pathogenesis and treatment of bronchopulmonary dysplasia. Curr Opin Pediatr. 2011;23(3):305-313. doi:10.1097/MOP.0b013e32834de57f
16. Coalson JJ. Pathology of bronchopulmonary dysplasia. Semin Perinatol. 2006;30(4):179-184. doi:10.1053/j.semperi.2006.05.004
17. Hansen AR, Barnès CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr. 2010;156(4):532-536. doi:10.1016/j.jpeds.2009.10.018
18. Foidart JM, Schaaps JP, Chantaine F, Munaut C, Lorquet S. Disregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEngodgin) in preeclampsia—a step forward but not the definitive answer. J Reprod Immunol. 2009;82(2):106-111. doi:10.1016/j.jri.2009.09.001
19. Jakkula M, Le Cras TD, Gebb S, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2000;279(3):L600-L607. doi:10.1152/ajlped.2000.279.3.L600
20. McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI workshop on the primary prevention of chronic lung diseases. Ann am Thorac Soc. 2014;11(3):146-153. doi:10.1513/AnnalsATS.201312-424LD
21. Shahzad T, Radajewski S, Chao CM, Bellusci S, Ehrhardt H. Pathogenesis of bronchopulmonary dysplasia: when inflammation meets organ development. Molecular and Cellular Pediatrics. 2016;3(1):23-31. doi:10.1186/s40348-016-0051-9
22. Yen T-A, Yang H-I, Hsieh W-S, et al. Preeclampsia and the risk of bronchopulmonary dysplasia in VLBW infants: a population based study. PloS One. 2013;8(9):e75168. doi:10.1371/journal.pone.0075168
23. Mullassery D, Smith NP. Lung development. Semin Pediatr Surg. 2015;24(4):152-155. doi:10.1053/j.sempedsurg.2015.01.011
24. Black FL, Woodall JP, Evans AS, Liebhaber H, HENLE, G. Prevalence of antibody against viruses in the Tiriyo, an isolated Amazon tribe. Am J Epidemiol. 1970;91(4):430-438. doi:10.1093/oxfordjournals.aje.a121153
25. Brown ER. Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus. J Pediatr. 1979;95(5):865-866. doi:10.1016/s0022-3476(79)80454-0
26. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claire N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr. 1996;128(4):470-478. doi:10.1016/s0022-3476(96)70356-6
27. Rojas MA, Gonzalez A, Bancalari E, Claire N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995;126(4):605-610. doi:10.1016/s0022-3476(95)70362-4
28. Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. J Clin Med. 2017;6(1):4-24. doi:10.3390/jcm6010004
29. Ambalavanan N, Morty RE. Searching for better animal models of BPD: a perspective. American Journal of Physiology.
30. Yee M, White RJ, Awad HA, Bates WA, McGrath-Morrow SA, O’Reilly MA. Neonatal hyperoxia causes pulmonary vascular disease and shortens life span in aging mice. *Am J Pathol.* 2011;178(6):2601-2610. doi:10.1016/j.ajpath.2011.02.010
31. Vento M, Moro M, Escrig R, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. *Pediatrics.* 2009;124(3):e439-e449. doi:10.1542/peds.2009-0434
32. Thekkeveedu RK, Guaman MC, Shivanna B. Bronchopulmonary dysplasia: a review of pathogenesis and pathophysiology. *Respir Med.* 2017;132:170-177. doi:10.1016/j.rmed.2017.10.014
33. Bhandari V, Bizzarro MJ, Shetty A, et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. *Pediatrics.* 2006;117(6):1901-1906. doi:10.1542/peds.2005-1414
34. Kazzi SN, Quasney MW. Deletion allele of angiotensin-converting enzyme is associated with increased risk and severity of bronchopulmonary dysplasia. *J Pediatr.* 2005;147(6):818-822. doi:10.1016/j.jpeds.2005.07.029
35. Manar MH, Brown MR, Gauthier TW, Brown LAS. Association of glutathione-S-transferase-P1 (GST-P1) polymorphisms with bronchopulmonary dysplasia. *J Perinatol.* 2004;24(1):30-35. doi:10.1038/sj.jp.7211202
36. Weber B, Borkhardt S, Stoll-Becker S, Reiss I, Gortner L. Polymorphisms of surfactant protein A genes and the risk of bronchopulmonary dysplasia in preterm infants. *Turk J Pediatr.* 2000;42(3):181-185.
37. Rova M, Haataja R, Marttila R, Ollikainen V, Tammela O, Reiss I, Gortner L. Increased risk of bronchopulmonary dysplasia and increased mortality in very preterm infants being small for gestational age. *Arch Gynecol Obstet.* 2003;269(1):40-44. doi:10.1007/s00404-003-0486-9
38. Eriksson L, Haglund B, Odlind V, Altman M, Ewald U, Kieler H. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia. *Acta Paediatr.* 2015;104(3):259-263. doi:10.1111/apa.12888
39. Bose C, Van Marter LJ, Laughon M, et al. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. *Pediatrics.* 2009;124(3):450-458. doi:10.1542/peds.2008-3249
40. Reiss I, Landmann E, Heckmann M, Misselwitz B, Gortner L. Increased risk of bronchopulmonary dysplasia and increased mortality in very preterm infants being small for gestational age. *Arch Gynecol Obstet.* 2003;269(1):40-44. doi:10.1007/s00404-003-0486-9
41. Augustine S, Avey MT, Harrison B, et al. Mesenchymal stromal cell therapy in bronchopulmonary dysplasia: systematic review and meta-analysis of preclinical studies. *Stem Cells Transl Med.* 2017;6(12):2079-2093. doi:10.1002/sctm.17-0126
42. Fung ME, Thébaud B. Stem cell-based therapy for neonatal lung disease: it is in the juice. *Pediatr Res.* 2014;75(1):2-7. doi:10.1038/pr.2013.176
43. Wu X, Xia Y, Zhou O, et al. Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children: study protocol for a randomized controlled trial (the MSC-BPD trial). *Trials.* 2020;21(1):125-135. doi:10.21203/rs.2.381/v1
Premature Infants. Identifier NCT03392467. 2018. https://clinicaltrials.gov/ct2/show/NCT03392467
57. National Library of Medicine (U.S.), Samsung Medical Center. Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia. Identifier NCT01632475. 2011. https://clinicaltrials.gov/ct2/show/NCT01632475
58. National Library of Medicine (U.S.), Children’s Hospital of Chongqing Medical University. Human Mesenchymal Stem Cells For Bronchopulmonary Dysplasia. Identifier NCT03558334. 2018. https://clinicaltrials.gov/ct2/show/NCT03558334
59. National Library of Medicine (U.S.), Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Caja. Human Mesenchymal Stem Cells for Bronchopulmonary Dysplasia Identifier NCT02443961. 2019. https://clinicaltrials.gov/ct2/show/NCT02443961
60. National Library of Medicine (U.S.), Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Stem Cells for Bronchopulmonary Dysplasia. Identifier NCT03378063. 2017. https://clinicaltrials.gov/ct2/show/NCT03378063
61. National Library of Medicine (U.S.), Children’s Hospital of Chongqing Medical University. Follow-Up Study of Mesenchymal Stem Cells for Bronchopulmonary Dysplasia. Identifier NCT03873506. 2018. https://clinicaltrials.gov/ct2/show/NCT03873506
62. National Library of Medicine (U.S.), Guangdong Women and Children Hospital. The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells. Identifier NCT03683953. 2018. https://clinicaltrials.gov/ct2/show/NCT03683953
63. National Library of Medicine (U.S.), Children’s Hospital of Chongqing Medical University. Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia. Identifier NCT01207869. 2010. https://clinicaltrials.gov/ct2/show/NCT01207869
64. National Library of Medicine (U.S.), Ottawa Hospital Research Institute. Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia. Identifier NCT04255147. 2022. https://clinicaltrials.gov/ct2/show/NCT04255147
65. National Library of Medicine (U.S.), Vinmec Research Institute of Stem Cell and Gene Technology. Umbilical Cord Mesenchymal Stem Cells Transplantation in the Treatment of Bronchopulmonary Dysplasia. Identifier NCT04062136. 2019. https://clinicaltrials.gov/ct2/show/NCT04062136
66. Liem NT, Anh TL, Thai T, Anh BV. Bone marrow mononuclear cells transplantation in treatment of established bronchopulmonary dysplasia: a case report. The American Journal of Case Reports. 2017;18:1090-1094. doi:10.12659/ajcr.905244
67. Lim R, Malhotra A, Tan J, et al. First-in-human Administration of Allogeneic Amnion Cells in premature infants with bronchopulmonary dysplasia: a safety study. Stem Cells Transl Med. 2018;7(9):628-635. doi:10.1002/sctm.18-0079
68. Baker CD. Long-term ventilation for children with chronic lung disease of infancy. Curr Opin Pediatr. 2019;31(3):357-366. doi:10.1097/MOP.0000000000000757
69. Chang YS, Oh W, Choi SJ, et al. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant. 2009;18(8):869-886. doi:10.3727/096369009X471189
70. Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med. 2009;180(11):1122-1130. doi:10.1164/rccm.200902-0242OC
71. Hansmann G, Fernandez-Gonzalez A, Aslam M, et al. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulmonary Circulation. 2012;2(2):170-181. doi:10.4103/2045-8932.97603
72. Kim CFB, Jackson EL, Woollenden AE, et al. Identification of bronchialveolar stem cells in normal lung and lung cancer. Cell. 2005;121(6):823-835. doi:10.1016/j.cell.2005.03.032
73. Abman SH, Matthey MA. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2009;180(11):1039-1041. doi:10.1164/rccm.200909-1330ED
74. Pierro M, Ionescu L, Montemurro T, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax. 2013;68(5):475-484. doi:10.1136/thoraxjnl-2012-202323
75. Chaput N, Théry C. Exosomes: immune properties and potential clinical implementations. Semin Immunopathol. 2011; 33(5):419-440. doi:10.1007/s00281-010-0233-9
76. Fan XL, Zhang Y, Li X, FuQL. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77(14):1-24. doi:10.1007/s00018-020-03454-6
77. Namba F. Mesenchymal stem cells for the prevention of bronchopulmonary dysplasia. Pediatr Int. 2019;61(10):945-950. doi:10.1111/ped.14001
78. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255-289. doi:10.1146/annurev-cellbio-101512-122326
79. Chen JY, An R, Liu ZJ, et al. Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats. Acta Pharmacol Sin. 2014;35(9):1121-1128. doi:10.1038/aps.2014.61
80. Dong J, Carey WA, Abel S, et al. MicroRNA-mRNA interactions in a murine model of hyperoxia-induced bronchopulmonary dysplasia. BMC Genomics. 2012;13(1):204-217. doi:10.1186/1471-2164-13-204
81. Cho BS, Kim JO, Ha DH, Yi YW. Exosomes derived from human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis. Stem Cell Research & Therapy. 2018;9(1):1-5. doi:10.1186/s13287-018-0939-5
82. Willis GR, Fernandez-Gonzalez A, Anastas J, et al. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med. 2018;197(1):104-116. doi:10.1164/rccm.201705-0925OC
83. Lee RH, Pulin AA, Seo MJ, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54-63. doi:10.1016/j.stem.2009.05.003
84. Parkar AA, Day AJ. Overlapping sites on the link module of human TSG-6 mediate binding to hyaluronan and chondroitin-4-sulphate. FEBS Lett. 1997;2-3(3):413-417. doi:10.1016/S0014-5793(97)00621-2

85. Milner CM, Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci. 2003;10(10):1863-1873. doi:10.1242/jcs.00407

86. Mittal M, Tiruppathi C, Nepal S, et al. TNFα-stimulated gene-6 (TSG6) activates macrophage phenotype transition to prevent inflammatory lung injury. Proc Natl Acad Sci. 2016;113(50):8151-8158. doi:10.1073/pnas.1614935113

87. Bryan C, Sammour I, Guerra K, et al. TNFα-stimulated protein 6 (TSG-6) reduces lung injury in an experimental model of bronchopulmonary dysplasia. Pediatr Res. 2019;85(3):390-397. doi:10.1016/s1390-9198-0250-2

88. Chaubey S, Thueson S, Ponnalagu D, et al. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxia. American Journal of Translational Research. 2016;8(2):342-353.

89. Ortiz LA, DeTrell M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci. 2007;104(26):11002-11007. doi:10.1073/pnas.0704421104

90. Geiser T, Atabai K, Jarreau PH, Ware LB, Pugin J, Matthay MA. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1 β-dependent mechanism. Am J Respir Crit Care Med. 2001;163(6):1384-1388. doi:10.1164/ajrccm.163.6.2006131

91. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance–by perinatal inflammation and hyperoxia. American Journal of Developmental Biology. 2020;8:1519-1541. doi:10.3389/fcell.2020.603292

92. Geiser T, Atabai K, Jarreau PH, Ware LB, Pugin J, Matthay MA. Pulmonary edema fluid from patients with acute lung injury augments in vitro alveolar epithelial repair by an IL-1 β-dependent mechanism. Am J Respir Crit Care Med. 2001;163(6):1384-1388. doi:10.1164/ajrccm.163.6.2006131

93. Mei SH, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance. Am J Respir Crit Care Med. 2010;182(8):1047-1057. doi:10.1164/rccm.201001-0010OC

94. Willis GR, Fernandez-Gonzalez A, Anastas J, et al. Mesenchymal stromal cell exosomes ameliorate experimental broncho-pulmonary dysplasia and restore lung function through macrophage immunomodulation. Am J Respir Crit Care Med. 2018;197(1):104-116. doi:10.1164/rccm.201705-0925OC

95. Li X, Zhang Y, Yeung SC, et al. Mitochondrial transfer of induced pluripotent stem cell-derived mesenchymal stem cells to airway epithelial cells attenuates cigarette smoke-induced damage. Am J Respir Cell Mol Biol. 2014;51(3):455-465. doi:10.1165/rcmb.2013-0529OC

96. Li X, Michaelouides C, Zhang Y, et al. Mesenchymal stem cells alleviate oxidative stress–induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141(5):1634-1645. doi:10.1016/j.jaci.2017.08.017

97. Li C, Cheung M, Han S, et al. Mesenchymal stem cells and their mitochondrial transfer: a double-edged sword. BioSci Rep. 2019;39(5):BSR20182417. doi:10.1042/BSR20182417

98. Li X, Michaelouides C, Zhang Y, et al. Mesenchymal stem cells alleviate oxidative stress–induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141(5):1634-1645. doi:10.1016/j.jaci.2017.08.017

99. Feng Y, Zhu R, Shen J, et al. Human bone marrow mesenchymal stem cells rescue endothelial cells experiencing chemotherapy stress by mitochondrial transfer via tunneling nanotubes. Stem Cells Dev. 2019;28(10):674-682. doi:10.1089/scd.2018.0248

100. Las G, Shirihai OS. Miro1: new wheels for transferring mitochondria. EMBO J. 2014;33(9):939-941. doi:10.1002/embj.201488441

101. Paliwal S, Chaudhuri R, Agrawal A, Mohanty S. Regenerative abilities of mesenchymal stem cells through mitochondrial transfer. J Biomed Sci. 2018;25(1):31-43. doi:10.1186/s12929-018-0429-1

102. Tang BL. Miro-working beyond mitochondria and microtubules. Cells. 2018;7(3):18-25. doi:10.3390/cells7030018

103. Ahmad T, Mukherjee S, Pattnaik B, et al. Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. EMBO J. 2014;9(9):994-1010. doi:10.1002/embj.201386030

104. Mohammadalipour A, Dumbali SP, Wenzel PL. Mitochondrial transfer and regulators of mesenchymal stromal cell function and therapeutic efficacy. Frontiers in Cell and Developmental Biology. 2020;8:1519-1541. doi:10.3389/fcell.2020.603292

105. Tseng N, Lambie SC, Huynh CQ, et al. Mitochondrial transfer from mesenchymal stem cells improves neuronal metabolism after oxidant injury in vitro: the role of Miro1. Journal of Cerebral Blood Flow & Metabolism. 2021;41(4):761-770. doi:10.1177/0271678X20928147

106. Mahrouf-Yorgov M, Augeul L, Da Silva CC, et al. Mesenchymal stem cells sense mitochondria released from damaged cells as danger signals to activate their rescue properties. Cell Death Differ. 2017;24(7):1224-1238. doi:10.1038/cdd.2017.51

107. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104-107. doi:10.1038/nature08780

108. Araujo JA, Zhang M, Yin F. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol. 2012;3:119-136. doi:10.3389/fphar.2012.00119

109. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759-765. doi:10.1038/nm.2736

110. Dutra Silva J, Su Y, Calfee CS, et al. Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. Eur Respir J. 2021;58(1):2002978. doi:10.1183/13993003. 02978-2020

111. Yang J, Ren Z, Zhang C, et al. Safety of autologous cord blood cells for preterms: a descriptive study. Stem Cells International. 2018;1-9. doi:10.1155/2018/5268057

112. Zhang J, Huang X, Wang H, et al. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Research & Therapy. 2015;6(1):1-7. doi:10.1186/s13287-015-0240-9
113. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. *Orphanet J Rare Dis*. 2007;2(1):35-44. doi:10.1186/1750-1172-2-35

114. Gronbach J, Shahzad T, Radajewski S, et al. The potentials and caveats of mesenchymal stromal cell-based therapies in the preterm infant. *Stem Cells International*. 2018;1-15. doi:10.1155/2018/9652897

115. Ashri NY, Ajlan SA, Aldahmash AM. Dental pulp stem cells. Biology and use for periodontal tissue engineering. *Saudi Med J*. 2015;36(12):1391-1399. doi:10.15537/smj.2015.12.12750

116. Hou T, Xu J, Wu X, et al. Umbilical cord Wharton’s jelly: a new potential cell source of mesenchymal stromal cells for bone tissue engineering. *Tissue Eng Part a*. 2009;15(9):2325-2334. doi:10.1089/ten.tea.2008.0402

117. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp Hematol*. 2005;33(11):1402-1416. doi:10.1016/j.exphem.2005.07.003

118. Sammour I, Somashekar S, Huang J, et al. The effect of gender on mesenchymal stem cell (MSC) efficacy in neonatal hyperoxia-induced lung injury. *PloS One*. 2016;11(10):e0164269. doi:10.1371/journal.pone.0164269

119. Tong Y, Zuo J, Yue D. Application prospects of mesenchymal stem cell therapy for bronchopulmonary dysplasia and the challenges encountered. *Biomed Res Int*. 2021;9983664. doi:10.1155/2021/9983664

120. Banda G, Tait J, Mittra J. Regenerative medicine as a disruptive technology: implications for manufacturing & clinical adoption. *Cell and Gene Therapy Insights*. 2019;5(10):1287-1303. doi:10.18669/cgti.2019.135

121. Moll G, Geißler S, Catar R, et al. Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy? *Biobanking and Cryopreservation of Stem Cells*. 2016;77-98. doi:10.1007/978-3-319-45457-3_7

122. Borghesi A, Avanzini MA, Novara F, et al. Genomic alterations in human umbilical cord-derived mesenchymal stromal cells call for stringent quality control before any possible therapeutic approach. *Cytotherapy*. 2013;15(11):1362-1373. doi:10.1016/j.jcyt.2013.06.006

123. Nitkin CR, Rajasingh J, Pisano C, Besner GE, Thébaud B, Sampath V. Stem cell therapy for preventing neonatal diseases in the 21st century: current understanding and challenges. *Pediatr Res*. 2020;87(2):265-276. doi:10.1038/s41390-019-0425-5

124. Chang YS, Choi SJ, Ahn SY, et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. *PloS One*. 2013;8(1):52419-52432. doi:10.1371/journal.pone.0052419

125. Brown DR, Biglan AW, Stretavsky MM. Retinopathy of prematurity: the relationship with intraventricular hemorrhage and bronchopulmonary dysplasia. *Journal of Pediatric Ophthalmology & Strabismus*. 1990;27(5):268-271. doi:10.3928/0191-3913-19900901-13

---

**How to cite this article:** Tang E, Zaidi M, Lim W-H, et al. Headway and the remaining hurdles of mesenchymal stem cells therapy for bronchopulmonary dysplasia. *Clin Respir J*. 2022;16(10):629-645. doi:10.1111/crj.13540